No annual revenue total was found in REVELATION BIOSCIENCES, INC.'s SEC filings.
Revelation Biosciences, Inc. (REVB) files with the SEC under industry code 2834, Pharmaceutical Preparations. As of Sep 30, 2026 it held $9.1 million in cash and investments and $805,399 in total debt.
Revenue
—
Net income (TTM)
$-12.16M
-49.6% vs year-ago TTM
Operating cash flow (TTM)
$-10.10M
-0.5% vs year-ago TTM
Free cash flow (TTM)
$-10.19M
EPS (TTM)
$-18.26
+95.5% vs year-ago TTM
Dividend per share
None
Shares outstanding
3.72M
+311.0% vs prior year
Net cash
$8.32M
as of Sep 30, 2026
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- REVB (Nasdaq), REVBW (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- San Diego, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1810560
- Former names
- Petra Acquisition Inc. (until Jan 11, 2022)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Operating income | -$9.1M | -$8.0M | -$8.7M | -$10.9M | — |
| Net income | -$8.9M | -$15.0M | -$120,254 | -$10.8M | -$12.0M |
| Diluted EPS | -$23.95 | -$1,052.16 | -$8.44 | -$149.20 | — |
| Operating cash flow | -$8.3M | -$18.3M | -$7.3M | -$11.2M | -$11.1M |
| Free cash flow | — | -$18.3M | — | — | -$11.2M |
| Total assets | $11.6M | $6.6M | $12.2M | $5.5M | $2.0M |
| Total liabilities | $2.7M | $1.9M | $5.6M | $4.5M | $2.1M |
| Stockholders' equity | $8.9M | $4.7M | $6.6M | $1.1M | -$99,470 |
| Cash and investments | $10.7M | $6.5M | $12.0M | $5.3M | $1.4M |
| Total debt | $746,784 | — | — | — | $16,752 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Results of operations
|
Nov 5, 2026 | Nov 5, 2026 |
| 10-Q | Quarterly report | Nov 5, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Officer or director change
|
Aug 19, 2026 | Aug 17, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 6, 2026 | Aug 6, 2026 |
| 10-Q | Quarterly report | Aug 6, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Material agreement, Change to shareholder rights, Bylaw or fiscal year change, Regulation FD disclosure
|
Jul 13, 2026 | Jul 10, 2026 |
All 389 Revelation Biosciences, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.